News

Research suggests that as metal allergies and implants grow in frequency, some patients may need to consult a dermatologist for treatment.

ICYMI, this week we had stories about session highlights from AAD 2023, FDA approvals of biosimilars and MCC treatments, the association between the Mediterranean diet and tumor response rates, and more.

The UK and Netherlands study assessed tumor response rates among 91 patients.

Researchers say the treatment is both safe and effective in moderate-to-severe cases.

Researchers say the impacts may be more harmful than those caused by industrial air pollutants.

More than 300 innovative sessions, an engaging exhibit hall, and heartfelt networking—there was a lot to pack into AAD 2023! Here are the highlights.

The study also found lasting benefits of the supplement for bone density up to age 4.

Study investigators said this system could have significant clinical implications.

The selective and reversible Janus kinase inhibitor is being studied in several immune-mediated inflammatory diseases.

Pregnant women with atopic dermatitis and psoriasis may require special treatment considerations.

In part 3 of this Frontline Forum series, Joshua Zeichner, MD, FAAD; Hilary Baldwin, MD; Zoe Diana Draelos, MD; Aaron S. Farberg, MD, FAAD; and Leon H. Kircik, MD, discuss the main pillars of acne and topical treatments available for patients with acne.

Miller shares upcoming news from the SDPA and important legislative updates for dermatology physician assistants.

DermaSensor’s handheld device is awaiting FDA review.

Researchers were unable to determine a definite correlation.

Researchers sought to analyze alopecia areata data in populations historically underrepresented in research.

Phase 3 data of Oleogel-S10 was presented in a late-breaking session at AAD 2023 in New Orleans.

Incyte’s MCC indication is approved under accelerated approval based on tumor response rate and duration of response.

Prior use of biologics in patients with plaque psoriasis may not impact the efficacy of risankizumab treatment.

Timber Pharmaceuticals is on its way to developing the first FDA-approved treatment for congenital ichthyosis subtypes.

Results from the phase 3 DERMIS-1 and DERMIS-2 trials were presented at the 2023 American Academy of Dermatology Annual Meeting.

A pediatric dermatologist and pediatric allergist translated guidelines into clinical practice at AAD 2023.

A pair of phase 3 trials met all primary and secondary endpoints after 48 weeks.

By week 24 of the phase 3 study, a quarter of participants felt their vitiligo had improved.

Sandoz, a Novartis division, expects to launch the new adalimumab biosimilar on July 1, 2023.

The use of tanning beds has become a popular practice in society today, however, it remains undisputed that ultraviolet radiation from natural sunlight and indoor tanning machines increases an individual’s risk of developing skin cancer.

Jack Arbiser, MD, PhD discusses the connection between the skin barrier and anti-aging products.

Results from the phase 3 study were presented at an AAD late-breaking research session.

A key session at the annual meeting will share practical advice and tools to better support you and your patients.

In a world where she practices dermatology, conducts research, and is a super mom, Alina Bridges, DO has nailed down a strategy to not let emails stress her out.